Literature DB >> 29487828

Long term outcomes for patients treated with half-fluence photodynamic therapy for chronic central serous chorioretinopathy: a case series.

Jennifer Doyle1, Bhaskar Gupta1, Irfan Tahir1.   

Abstract

A case series was used to evaluate the efficacy of half-fluence photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSCR). Patients were treated with standard-dose verteporfin and half-fluence PDT. Totally 13 eyes from 11 patients were included. The mean patient age was 52.0y. There was a mean reduction in central retinal thickness of 107.0 microns. Totally 7/13 eyes (53.8%) achieved resolution of subretinal fluid (SRF) on optical coherence tomography (OCT) scan after 1 treatment with PDT. Four eyes had further treatment with PDT; of these 1 eye achieved resolution of SRF. Seven of the 13 eyes (53.8%) achieved an improvement of more than 5 ETDRS letters. One patient experienced acute macula oedema 1d post PDT treatment. These results support the hypothesis that half-fluence PDT can have a positive effect in chronic CSCR for a gain in visual acuity and reduction in sub-retinal fluid. Acute macula oedema is a rare but potential adverse effect of half-fluence PDT.

Entities:  

Keywords:  central serous chorioretinopathy; fluence; photodynamic therapy

Year:  2018        PMID: 29487828      PMCID: PMC5824093          DOI: 10.18240/ijo.2018.02.25

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  24 in total

1.  Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Alexandros Rouvas; Panagiotis Stavrakas; Panagiotis G Theodossiadis; Polyxeni Stamatiou; Maria Milia; Emmanuela Giannakaki; Ioannis Datseris
Journal:  Eur J Ophthalmol       Date:  2012 May-Jun       Impact factor: 2.597

2.  Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.

Authors:  Massimo Nicoló; Chiara M Eandi; Camilla Alovisi; Federico M Grignolo; Carlo Enrico Traverso; Donatella Musetti; Felice Cardillo Piccolino
Journal:  Am J Ophthalmol       Date:  2014-01-30       Impact factor: 5.258

3.  One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Kyoko Fujita; Yutaka Imamura; Kei Shinoda; Celso Soiti Matsumoto; Yoshihiro Mizutani; Kouhei Hashizume; Atsushi Mizota; Mitsuko Yuzawa
Journal:  Ophthalmology       Date:  2014-11-18       Impact factor: 12.079

4.  Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study.

Authors:  T Y Y Lai; W-M Chan; H Li; R Y K Lai; D T L Liu; D S C Lam
Journal:  Br J Ophthalmol       Date:  2006-04-05       Impact factor: 4.638

5.  Influence of treatment parameters on selectivity of verteporfin therapy.

Authors:  Stephan Michels; Fabian Hansmann; Wolfgang Geitzenauer; Ursula Schmidt-Erfurth
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-01       Impact factor: 4.799

6.  Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy.

Authors:  Yong-Kyu Kim; Na-Kyung Ryoo; Se Joon Woo; Kyu Hyung Park
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-01-24       Impact factor: 3.117

7.  Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.

Authors:  Eva Smretschnig; Siamak Ansari-Shahrezaei; Stefan Hagen; Carl Glittenberg; Ilse Krebs; Susanne Binder
Journal:  Retina       Date:  2013-02       Impact factor: 4.256

8.  Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial.

Authors:  Michele Reibaldi; Nicola Cardascia; Antonio Longo; Claudio Furino; Teresio Avitabile; Salvatore Faro; Marisa Sanfilippo; Andrea Russo; Maurizio Giacinto Uva; Ferdinando Munno; Vincenzo Cannemi; Marco Zagari; Francesco Boscia
Journal:  Am J Ophthalmol       Date:  2009-11-06       Impact factor: 5.258

9.  COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.

Authors:  Cheng-Kuo Cheng; Chun-Kai Chang; Chi-Hsien Peng
Journal:  Retina       Date:  2017-02       Impact factor: 4.256

10.  Half-fluence photodynamic therapy to treat chronic central serous chorioretinopathy: A case series.

Authors:  Ahmed S Al-Hinai; Mohammed S Al-Abri
Journal:  Oman J Ophthalmol       Date:  2011-05
View more
  2 in total

1.  Longitudinal follow-up and outcome analysis in central serous chorioretinopathy.

Authors:  Niroj Kumar Sahoo; Joshua Ong; Amrish Selvam; Dmitri Maltsev; Riccardo Sacconi; Ramesh Venkatesh; Nikitha Gurram Reddy; Shivam Madan; Beatrice Tombolini; Luiz H Lima; Varsha Pramil; Giridhar Anantharaman; Antonio Marcelo Casella; Gerardo Ledesma-Gil; Nadia Waheed; Enrico Borrelli; Giuseppe Querques; Jay Chhablani
Journal:  Eye (Lond)       Date:  2022-04-01       Impact factor: 3.775

Review 2.  Management of chronic central serous chorioretinopathy.

Authors:  Daren Hanumunthadu; Anna C S Tan; Sumit Randhir Singh; Niroj Kumar Sahu; Jay Chhablani
Journal:  Indian J Ophthalmol       Date:  2018-12       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.